decisionhealth Newsletters, Part B News - 2022 Issue 2 (February)
Prescribing ivermectin for COVID isn’t illegal but could raise compliance flags
Subscribe or sign in to view the full article.
Article Overview
This article examines whether prescribing ivermectin for COVID-19 can create legal or compliance exposure for clinicians even when the prescription is off-label and not billed to insurance. It is aimed at providers, compliance staff, and coding or risk-management readers who need a high-level understanding of malpractice concerns, board discipline risk, and related state-legislative activity, along with references to public health guidance and a proposed Kansas measure.
Why This Topic Matters
It helps readers understand that off-label prescribing can still raise professional and regulatory concerns, especially when practice standards, licensing boards, or state legislation are involved.
Article Sections
-
Question
Introduces the scenario involving a physician prescribing ivermectin for COVID-19 and asks whether the practice could create trouble.
-
Answer
Provides the article’s main discussion of off-label prescribing, malpractice exposure, and compliance considerations.
-
Resources
Lists external references, including public health guidance and a proposed state legislative measure related to COVID-19 treatment.
What You Will Learn
- How the article frames off-label prescribing in relation to legal and compliance risk
- What broad types of professional exposure are discussed in connection with COVID-19 treatment decisions
- Which public resources and legislative references are cited as context for the discussion
- How the article distinguishes between billing issues and broader clinical or regulatory concerns
Who Should Read This
- Physicians
- Practice managers
- Compliance officers
- Healthcare attorneys
- Medical billing and coding professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com